The Consumer Health product portfolio includes a variety of non-prescription drugs and health care products, sold through pharmacies and drugstores. The portfolio includes both Navamedic’s owned and in-licensed brands. Future sales are secured through pharmacy chain agreements in the Nordic countries, including Benelux. Navamedic has local knowledge and market insight with a footprint in each country. With a competent Sales & Marketing department and sales force in each country, Navamedic work directly with Wholesales, Pharmacy Chains, Doctors and Consumers.
Specialty pharma consist of selected therapeutic areas where Navamedic have extensive internal knowledge. Our regulatory, marketing and sales team have long-time working experience in the pharmaceutical sector. Through daily interactions with professionals at different levels of the healthcare sector Navamedic ensures that we provide updated information and support regarding our products, which will help physicians and nurses to treat their patients. Navamedic have strong professional relationships with experts within each targeted medical field. We also have a solid platform and know-how regarding market access in our markets. Our aim is to be a highly reliable partner to healthcare professionals in all our therapeutic areas.
The Medical nutrition business segment is based on the sale of products for the treatment of inborn errors of metabolism (IEM). It includes the distribution agreement with the UK based Company Vitaflo International ltd for the Nordic region. Vitaflo International have over 30 years of experience in producing specialist nutritional product for inborn errors of metabolism (IEM).
Medical nutrition itemlist
A generic drug is a pharmaceutical drug consisting of the same chemical substance as a drug that was originally protected by chemical patents. Generic drugs are allowed for sale after the patents on the original drugs expire. Because the active chemical substance is the same as in the original drug, the medical profile of generics is believed to be equivalent in performance.